However, today’s recommendations against their use reflect uncertainty about how the drug produces effects in the body and evidence of little or no effect on survival and vital measures. such as risk of hospitalization and need for mechanical ventilation. There is also a lack of reliable data on severe COVID-19-related harm associated with these drugs.
WHO advice against the use of fluvoxamine except in clinical trials is informed by data from three randomized controlled trials (RCTs) of more than 2,000 patients and their strong advice for colchicine was based on data from seven RCTs with 16,484 patients.
Advertisement
After scrutinizing this evidence, the panel, which included experts from around the world, including four patients who had contracted COVID-19, concluded that almost all patients were well understood. would choose not to treat with fluvoxamine or colchicine for COVID-19 based on the Available Evidence.
The panel noted that none of the studies included pediatric registries, so the applicability of these recommendations to children is uncertain. However, they did not see why children with COVID-19 would respond differently to treatment with fluvoxamine or colchicine.
Today’s recommendations are part of a life guide, developed by the World Health Organization with methodological support from the MAGIC Evidence Ecosystem Organization, to provide reliable guidance on the management of manage COVID-19 and help doctors make better decisions with their patients.
The Living Guide allows researchers to update previously reviewed evidence summaries and peer review as new information becomes available.
Previously, WHO issued strong recommendations for the use of nirmatrelvir and ritonavir, and conditional recommendations for sotrovimab, remdesivir and molnupiravir for patients at high risk for non-severe COVID-19.
For patients with severe COVID-19, WHO specifically recommends corticosteroids, the addition of an IL-6 receptor blocker or baricitinib, but advises against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with COVID- 19 regardless of disease severity.
Source: Eurekalert
